at Zacks.com (Jan 7, 2015)
Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox liver-cancer treatment with China's Hisun, which will pay $5M upfront and manufacture the drug. The deal is a precursor to a China licensing agreement that could be worth hundreds of millions of dollars to Celsion, and comes ahead of the results of Phase III trials for ThermoDox. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at MarketWatch.com (Mar 8, 2013)
at MarketWatch.com (Jan 15, 2013)
at MarketWatch.com (Dec 27, 2012)
at Fox Business (Aug 23, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs